Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Actinium-225-macropa-pelgifatamab in advanced metastatic castration-resistant prostate cancer
NL-OMON59910Phase 1Active, not recruiting
- Sponsor
- Bayer
- Start
- Jun 2024
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Alpha Emitters → Radiopharmaceuticals, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of actinium-225-macropa-pelgifatamab in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Bayer. Primary endpoint: Primary endpoint(s). Started Jun 2024; status: active, not recruiting.
02
Drugs
actinium-225-macropa-pelgifatamab
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NL-OMON59910.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59910.